Document:

Exhibit
10.43

 

Investigator
Initiated Study Agreement (Drug)

 

This
Agreement is entered into by and between Thomas Jefferson University, a Pennsylvania non-profit corporation, with an address
at Office of Research Administration, 125 South 9th Street, Second Floor Sheridan Philadelphia, PA 19107,
hereinafter called “Institution,” and BriaCell Therapeutics, a corporation with its principal office and place of
business at 820 Heinz Avenue, Berkeley, CA 94710, hereinafter called “Sponsor.”

 

Background

 

Institution
has entered or will enter into a separate agreement with MERCK SHARP & DOHME CORP. (hereinafter (“Merck”), whose
drug Pembrolizumab (MK-3475) (the “Merck Drug”) is being used in the Study in combination with the BriaCell Drug (WV-BR-1-GM),
relative to Merck’s support for the Study (hereinafter “Merck Agreement”);

 

The
research program contemplated by this Agreement is of mutual interest and benefit to the Institution and to the Sponsor, and will
further the Institution’s instructional and research objectives in a manner consistent with its status as a non-profit,
tax-exempt, educational institution. In consideration of the promises and mutual covenants contained herein, and intending to
be legally bound hereby, the parties hereto agree as follows; and

 

BriaCell,
consistent with its commitment to clinical research, wishes to provide certain support to Institution on the terms and conditions
described in this Agreement.

 

Terms

 

	1.	Scope of Work

 

The
Institution shall carry out the research (“Study”) set forth in the Protocol entitled “A Phase I/II Study of
the SV-BR-1-GM Regimen in Metastatic Breast Cancer Patients with HLA match in Combination with Pembrolizumab” MISP #58523
(the “Protocol”) and attached hereto as Exhibit A (“Protocol”) in accordance with this Agreement. The
Protocol is incorporated into this Agreement by reference. In the event of any inconsistency between this Agreement and the Protocol,
the terms of this Agreement shall govern. Changes in the Protocol may be made only through prior written Agreement between the
Sponsor and the Institution. Sponsor agrees that the Protocol shall be amended to the extent Institution’s Institutional
Review Board (“IRB”) makes or conditions other requirements. In such an event, Sponsor shall have the right within
thirty (30) days after notification of such, to terminate the Agreement. The parties agree that approval of the Protocol by Institution’s
IRB is a condition precedent to the parties’ rights and duties hereunder with respect to such Protocol. Work shall not begin
until such time as all IRB requirements are fully met. Institution represents and certifies that the terms and conditions of the
Merck Agreement are consistent with BriaCell’s rights hereunder and do not conflict with the terms and conditions of this
Agreement.

 

    	 	1	 

    	 

    

 

	2.	Principal Investigator

 

Institution’s
Principal Investigator is Saveri Bhattacharya, DO an employee of Institution, hereinafter called “Principal Investigator”,
who will be responsible for the direction of the Study in compliance in all material respects with the Protocol, applicable Institution
policies, generally accepted standards of good clinical practice, all applicable local, state and federal laws and regulations
governing the performance of clinical investigations. If for any reason, the above named individual is unwilling or unable to
continue to serve as Principal Investigator and a successor, acceptable to both the Institution and the Sponsor is not available,
this Agreement may be terminated as provided in Article 14. Approval of a successor shall not be unreasonably withheld by either
party.

 

	3.	Performance Period

 

The
effective period of this Agreement will be from the date of execution of this Agreement and will continue until completion of
the obligations established in this Agreement and the Protocol unless otherwise terminated in accordance with Article 14. The
effective period may be extended by the mutual written consent of the parties hereto, as provided in Article 25. The Study may
not begin until approval is received from the Institution’s IRB and this Agreement is fully executed by Institution and
Sponsor, and is signed and acknowledged by the Principal Investigator.

 

	4.	COST AND PAYMENT

 

	A.	As
                                         consideration for performance under the terms of this Agreement, Sponsor shall pay the
                                         Institution a total in accordance with the attached budget. Payment shall be made to
                                         the Institution according to the attached budget appended hereto and incorporated herein
                                         by reference. All costs outlined on the budget shall remain firm for the duration of
                                         the Study, unless otherwise agreed in writing by the Institution and Sponsor. If not
                                         separately listed in the budget for payments to Site, an IRB fee of $3,200 will be assessed
                                         by Site for initial IRB review and approval. An IRB fee of $1,100 will be assessed by
                                         Site for any amendment requiring full IRB review. Sponsor will reimburse Site upon receipt
                                         of invoice.

 

	B.	Checks
                                         will be made payable to: “Thomas Jefferson University.” Checks or accompanying
                                         letter will reference this Agreement and the Principal Investigator’s name and
                                         will be sent to:

 

Thomas
Jefferson University

125 S. 9th Street

Second
Floor Sheridan

Philadelphia,
PA 19107

 

Institution
Tax Identification Number - 23-1352651

 

	5.	Recordkeeping

 

	A.	The
                                         Institution and the Principal Investigator shall prepare and maintain records, reports
                                         and data for a period of two (2) years following the FDA’s approval of the Study
                                         Drug, or after the investigation of the Study Drug has ended, pursuant to U.S. 21 CFR
                                         312.62 Sponsor shall notify Institution promptly following the FDA’s approval,
                                         or after the investigation of the Study Drug has so ended.

 

    	 	2	 

    	 

    

 

	B.	Institution
                                         shall cooperate with the lawful and proper requests of any regulatory authority with
                                         appropriate jurisdiction and allow them reasonable access to relevant study records and
                                         data.

 

	C.	Institution
                                         shall cooperate with Sponsor in making records, reports and data developed under this
                                         Agreement available to the Sponsor upon reasonable advance notice during Institution’s
                                         normal business hours. Sponsor may utilize all data and results for any reasonable purpose,
                                         including regulatory submissions.

 

	D.	For each research subject participating in the Study,
Principal Investigator shall prepare and submit to Sponsor all original case report forms as required by the Protocol. Such case
report forms shall be the property of Sponsor and a copy to be retained by the Institution. Institution retains ownership of all
medical records.

 

	6.	Material Transfer

 

	A.	During
                                         the course of the Study, Sponsor will provide and deliver to Institution study drug or
                                         drugs SV-BR-1-GM as Sponsor determines necessary for the conduct of the Study (the “Study
                                         Drug(s)”) at no expense to Institution. Upon termination of the Study or this Agreement,
                                         Sponsor shall notify Institution if the Study Drugs provided by Sponsor should be promptly
                                         returned to Sponsor at Sponsor’s expense. If Institution does not receive such
                                         notice, the Study Drugs may be retained, used or destroyed at Sponsor’s expense.

 

	B.	Institution
                                         and Investigator: (i) shall use the Study Drug only to conduct the Study in accordance
                                         with the Protocol; (ii) shall not modify the Study Drug, except if specifically required
                                         by the Protocol; and (iii) shall handle, store, and ship or dispose and destroy the Study
                                         Drug in compliance in all material respects with applicable local, state, and federal
                                         laws, rule, and regulations.

 

	C.	Sponsor
                                         represents and warrants that it is in compliance with federal, state, and local legal
                                         requirements relating to the manufacture and formulation of the Study Drug. Sponsor shall
                                         report to Institution any adverse events or findings of which Sponsor becomes aware relating
                                         to the Study Drug and shall furnish a copy of any safety report to Institution at the
                                         time it is furnished to the FDA. Sponsor also agrees to notify Institution of any events
                                         or concerns about the safety of Study Drug that arise during the term of this Agreement
                                         even if these events or concerns do not meet the definition of an adverse event requiring
                                         notification to the FDA.

 

	D.	The
                                         Institution shall report any adverse events or adverse drug reactions (each as defined
                                         in the Protocol) that arise in relation to the Study to (i) the relevant Regulatory Authorities
                                         in accordance with the Applicable Laws; and (ii) any overseeing Institutional Review
                                         Board and (iii) the Sponsor in accordance with the protocol. The Institution shall provide
                                         the Sponsor with any suspected and unexpected serious adverse drug reactions (SUSARs)
                                         in expedited manner at the same time these are reported to regulatory authority and/or
                                         IRB.

 

    	 	3	 

    	 

    

 

	7.	Confidential Information

 

	A.	For
                                         purposes of the Agreement, “Confidential Information” means confidential
                                         information of Sponsor directly related to the Study that is disclosed to Institution
                                         by Sponsor in writing and conspicuously marked as confidential and proprietary at the
                                         time of disclosure, or, if disclosed visually or orally, is stated to be confidential
                                         and proprietary at the time of disclosure and confirmed by a written summary describing
                                         the information in reasonable detail delivered by Sponsor to Institution within fifteen
                                         (15) days after disclosure given the understanding that failure to do so does not constitute
                                         a designation of non-confidentiality, when the confidential nature is apparent from context
                                         and subject matter. Sponsor shall not disclose confidential information to the Institution
                                         unless it is necessary and essential to the Study. Institution shall protect Sponsor’s
                                         Confidential Information with the same degree of care as Institution’s own confidential
                                         information. The Institution retains the right to refuse to accept any Confidential Information
                                         that the Principal Investigator does not consider to be essential to the performance
                                         of the Study.

 

	B.	All
                                         information supplied by Institution to Sponsor, including, but not limited to, the Protocol
                                         are considered confidential and shall remain the sole property of the Institution (“Institution’s
                                         Confidential Information”). Sponsor shall treat Institution’s Confidential
                                         Information with the same degree of care as its own Confidential Information.

 

	C.	The
                                         parties’ obligations of confidentiality will exist during the performance of this
                                         Agreement and for three (3) years following termination or expiration of this Agreement.

 

Notwithstanding
anything to the contrary contained in this Agreement or the markings on any document disclosed by Sponsor, Confidential Information
does not include information that:

 

		(i)	information
                                         that is reasonably required by scientific standards for publication of the Study results,
                                         or any information that is necessary for other scholars to verify the results of the
                                         Study;

 

		(ii)	information
                                         that is in the public domain at the time Sponsor discloses it to Principal Investigator
                                         or that thereafter enters the public domain through no fault of Principal Investigator;

 

		(iii)	information
                                         that was known to Principal Investigator or to Institution before the date Sponsor discloses
                                         it to Principal Investigator, or that becomes known to Principal Investigator or the
                                         Institution through a third party having an apparent bona fide right to disclose the
                                         information;

 

		(iv)	information
                                         that is independently developed by Institution personnel;

 

		(vi)	information
                                         that is disclosed by Principal Investigator or Institution in accordance with the terms
                                         of Sponsor’s written approval; and

 

		(vii)	information
                                         that is required to be disclosed for compliance with any federal, state or local law
                                         or regulation, or required to be disclosed by a court of law or governmental authority.

 

Notwithstanding
the foregoing, Sponsor shall cooperate and authorize release of data, which is the subject of this Study, to Institution’s
internal committees as required by accrediting agencies or other governmental agencies. If required to report such data to any
governmental authority or agency, Institution shall use reasonable efforts to maintain the confidentiality of such data. Institution
reserves the right to disclose such Confidential Information to third party payors or government agencies as necessary in order
to obtain reimbursement for medical services provided to Study subjects that are not otherwise reimbursed by the Sponsor.

 

 

    	 	4	 

    	 

    

 

	D.	In
                                         the event the Sponsor shall come into contact or otherwise have access to Study subject’s
                                         medical records, the Sponsor shall hold in confidence the identity of the subject and
                                         shall comply with all applicable law(s) regarding the confidentiality of such records.
                                         Sponsor will review and approve the Informed Consent document. Sponsor agrees that, should
                                         Sponsor gain access to any protected health information of Study subjects, Sponsor will
                                         treat such protected health information in accordance with the Informed Consent document,
                                         any Authorization document, and all applicable federal, state, and local laws and regulations
                                         governing the confidentiality and privacy of individually identifiable health information,
                                         including without limitation, the Health Insurance Portability and Accountability Act
                                         of 1996 (“HIPAA”) and any regulations promulgated thereunder. If Sponsor
                                         gains access to any protected health information that is not covered by the Informed
                                         Consent or Authorization, Sponsor shall hold such information in the strictest confidence,
                                         shall not remove records containing such information from the Institution and, if inadvertently
                                         removed, shall immediately return any records containing such information to the Institution.
                                         In no event shall Sponsor use or disclose protected health information for any purpose
                                         other than as specifically set forth in the aforementioned Informed Consent and/or authorization.
                                         Sponsor must report to Institution any use or disclosure of which Sponsor becomes aware
                                         not provided for in the Informed Consent and/or authorization.

 

	E.	The
                                         parties agree to take such additional steps and/or to negotiate such amendments to the
                                         Agreement as may be required to ensure that the parties are and remain in compliance
                                         with the HIPAA regulations and official guidance.

 

	F.	All
                                         protected health information shall be treated as confidential by Institution in accordance
                                         with all applicable federal, state or local laws and regulations governing the confidentiality
                                         and privacy of individually identifiable health information, including without limitation,
                                         the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”)
                                         and any regulations and official guidelines promulgated thereunder.

 

	8.	Data, Publications

 

		A.	The
                                         Principal Investigator and Institution shall be free to publish and present the results
                                         and data of the Study in accordance with the following:

 

		i.	At
                                         least thirty (30) days prior to submitting a manuscript or abstract for publication or
                                         presentation Principal Investigator will submit to Sponsor a copy of the abstract, manuscript
                                         or presentation for review and comment, which comments will be given due consideration
                                         by Principal Investigator. Sponsor shall have thirty (30) days to review and respond
                                         to Institution with comments. Sponsor may request Institution to remove any Confidential
                                         Information, however, other than ensuring the protection of Confidential Information,
                                         Sponsor shall not exercise editorial control over the publication. In addition, Principal
                                         Investigator shall delay any proposed publication/presentation an additional thirty (60)
days in the event Sponsor so requests in writing to enable Sponsor to secure patent or other proprietary protection of any inventions
or discoveries in such publication/presentation.

 

    	 	5	 

    	 

    

 

		ii.	Any
                                         such publication or presentation shall acknowledge, if appropriate, the contribution
                                         of Sponsor, its employees, agents and representatives.

 

Notwithstanding
the foregoing, the Institution and Principal Investigator shall have the right to publish the results of the Study and any background
information provided by Sponsor that is necessary to include in any publication of research results or necessary for other scholars
to verify such Study results.

 

	9.	Patents and Inventions

 

	A.            	Study Drug

 

Sponsor
shall own improvements, which include new formulations, or new dosages of the Study Drug (“Study Drug Improvements”)
or enhancements in the operation, cost of operation, manufacture, or packaging of the Study Device (“Study Device Improvements”),
which are conceived and /or reduced to practice in the performance of the Clinical Trial during the term of this Agreement. Sponsor
shall grant Institution a non-exclusive, royalty-free, nonsublicensable, non-transferable license to use such Study Drug or Study
Device Improvement for its internal, non-commercial, academic research purposes and patient care.

 

	B.             	Research Results

 

Institution
retains ownership of all data, data analysis, test results, medical records, laboratory notes and notebooks, techniques, progress
reports, and any other results (collectively “Research Results”) that are obtained in Institution’s performance
of the Clinical Trial. Institution shall grant Sponsor a non-exclusive, royalty-free, worldwide, non-transferable, nonsublicensable
license to use Research Results. BriaCell acknowledges and agrees that Institution will share such Study data and results with
Merck in accordance with the Merck Agreement, provided that Institution shall not share any data and results with Merck that relate
solely to the BriaCell Drug. Except for Merck and other than through the publication process outlined in this Article 8, Institution
agrees not to provide any other commercial third party with access to or with the right to use the data or results for any purpose
without the written permission of BriaCell which shall not be unreasonably withheld.

 

Sponsor
shall consult with Institution’s Innovation Pillar for a license to use Research Results that support patentable Institution
Inventions or Joint Inventions or copyrighted or copyrightable works of the Institution, as defined under Inventions.

 

	C.             	Inventions and Invention Disclosure

 

Inventions
as referenced herein do not include Study Drug Improvements or Study Device Improvements but shall include any discovery, which
shall include any new use or indication of the Study Drug or Study Device that is outside the direct scope of the Study Drug or
Study Device, method, tangible research material, development, know-how, design or process conceived and/or reduced to practice
in the performance of the Clinical Trial during the term of this Agreement.

 

Inventions
shall include, but not be limited to, all United States and foreign patent applications claiming said patentable inventions,
including any divisional, continuation, continuation-in-part (to the extent that the claims are directed to said patentable
Inventions), and foreign equivalents thereof, as well as any patents issued thereon or reissues or reexaminations
thereof.

 

Inventions
also include all significant copyrightable software created in the conduct of the Clinical Trial during the term of this Agreement.

 

    	 	6	 

    	 

    

 

Except
for Study Drug or Study Device Improvements, inventorship on Inventions, whether or not patentable, that are conceived and/or
reduced to practice in the performance of the Clinical Trial shall be determined in accordance with the principles of United States
patent law and ownership shall follow inventorship. Employees of Institution have an obligation to assign their intellectual property
rights to Institution.

 

Inventions
conceived and/or reduced to practice solely by Institution employees in the performance of the Clinical Trial shall belong to
Institution (“Institution Inventions”). Institution shall retain all right, title and interest in and to the Institution
Inventions.

 

Inventions
conceived and/or reduced to practice solely by Sponsor employees in the performance of the Clinical Trial shall belong to Sponsor
(“Sponsor Inventions”). Sponsor shall retain all right, title and interest in and to the Sponsor Inventions and in
and to Study Drug or Study Device Improvements.

 

Inventions
conceived and/or reduced to practice jointly by Institution employees and by Sponsor employees in the performance of the
Clinical Trial shall belong jointly to Institution and Sponsor (“Joint Inventions”). Institution and Sponsor
shall have an undivided, half interest in and to the Joint Inventions.

 

Institution’s
Innovation Pillar shall promptly notify Sponsor upon receipt of an invention disclosure on an Institution Invention or a Joint
Invention. Institution may disclose Institution Inventions (excluding BriaCell Drug Inventions, defined below) to Merck at the
same time as they disclose them to BriaCell.

 

Therapies
that involve the use of the BriaCell Drug in combination (i.e. concurrently, concomitantly, sequentially, etc.) with the Merck
Drug, including without limitation, therapeutic uses, indicators of response and methods related to such combined use of the Merck
Drug and the BriaCell Drug shall be referred to herein as “Other Inventions”. Institution shall promptly disclose
any Other Inventions to BriaCell in writing. Institution hereby grants to BriaCell a paidup, non-exclusive royalty free, sub-licensable,
worldwide license to all Other Inventions for any legitimate business purpose. In addition, Institution hereby grants to BriaCell
a co-exclusive (with Merck) option to obtain a co-exclusive (with Merck) license to all Other Inventions for any legitimate business
purpose.

 

	D.            	Patent Prosecution

 

Sponsor
shall advise Institution in writing, no later than sixty (60) days following notification of an invention disclosure by Institution’s
Innovation Pillar, whether it requests Institution to file and prosecute patent applications on such Institution Invention or
Joint Invention at Sponsor’s expense. If Sponsor does not request Institution to file and prosecute such patent applications
within 60 days following notification of the invention disclosure, Institution may at its discretion proceed with such preparation
and prosecution at its own cost and expense; but such patent applications shall be excluded from Sponsor’s option described
below.

 

Institution
shall control the preparation and prosecution of all patent applications and the maintenance of all patents related to such Institution
Invention or Joint Invention. With regard to any patent applications filed at the written request and expense of Sponsor, Institution
will consult with Sponsor on patent prosecution, and Sponsor shall have the opportunity to provide comment, in a timely manner,
on such patent prosecution and maintenance. Sponsor shall reimburse Institution within thirty (30) days upon receipt of invoice
for all documented expenses incurred in connection with the filing and prosecution of the patent applications and maintenance
of the patents that Sponsor has requested Institution to prosecute.

 

    	 	7	 

    	 

    

 

	E.            	Licenses and Options

 

Upon
Institution’s Innovation Pillar notifying Sponsor of an invention disclosure on an Institution Invention or a Joint Invention,
and to the extent owned and controlled by Institution and available for licensing, Institution shall grant Sponsor (i) a non-exclusive,
worldwide, royaltyfree, non-transferable, non-sublicensable license and (ii) a sixty (60) day option (the “Option Period”)
to negotiate an exclusive, worldwide, royalty-bearing, fully sublicensable license to the Institution Invention or Institution’s
rights in the Joint Invention. Sponsor shall exercise the option by written notification to Institution’s OTT prior to the
expiration of the 60 day Option Period and the parties shall then commence good faith negotiation, not to exceed six (6) months
(the “Negotiation Period”) from the date Institution receives Sponsor’s written notification exercising the
option, to determine the terms of an exclusive commercial license agreement. If Sponsor does not exercise the option, or if Sponsor
and Institution fail to execute an exclusive license agreement within three (3) months following the expiration of the Negotiation
Period, Institution shall be free to license the Institution Invention or Institution’s rights in Joint Inventions to any
party upon such terms as Institution deems appropriate.

 

Sponsor
shall keep Researcher fully informed, on at least an annual basis, as to the commercial development of any Joint Inventions (the
“Annual Joint Invention Report”). If the Joint Invention is licensed, sublicensed, assigned or otherwise transferred
to a party, Researcher shall be entitled to share in the compensation or fees received by Sponsor on terms to be negotiated by
Researcher and Sponsor (“Joint License Fees”). To the extent a Joint Invention is developed such that Sponsor receives
any compensation, fees, royalties or other consideration of which the Joint Invention is a part, Researcher shall share in such
consideration on terms to be negotiated (“Joint Revenue”). If within the Option Period, Sponsor desires an Exclusive
License to Researcher’s rights in the Joint Invention, then Sponsor shall exercise this option during the Option Period
and if an Exclusive License is executed, there shall be no Annual Joint Invention Report, Joint License Fees or Joint Revenues
and the terms of the Exclusive License shall control.

 

Upon
exercising the option, Sponsor shall be responsible for patent expenses that it has requested Institution to file on the Institution
Invention or Joint Invention during the Option Period, Negotiation Period, and the 3 months following the expiration of the Negotiation
Period when both parties are in the process of executing the exclusive license agreement.

 

Any
license granted to Sponsor shall be subject to Institution’s right to use and permit other non-profit organizations to
use Institution Inventions and Joint Inventions for educational and research purposes and patient care, and, if applicable,
to the rights of the United States government reserved under Public Laws 96-517, 97-256 and 98-620, codified at 35 U.S.C.
200-212, and any regulations issued thereunder.

 

	10.	Use of the Institution’s or Sponsor’s Name
(Advertising)

 

The
Institution and the Sponsor will obtain prior written permission from each other before using the name, symbols, logotypes and/or
marks of the other in any form of publicity in connection with the Study. This shall not include legally required disclosure by
the Institution or Sponsor that identifies the existence of the Agreement. Further, Sponsor’s use of the name, symbols and/or
marks of Institution, or names of Institution’s employees, shall be limited to identification of Institution as the Study
site and the Study staff as participants in the Study. Notwithstanding the forgoing, Institution may disclose the title of the
Study, the funding amount and the identity of the Sponsor in federal grant applications or to fulfill internal reporting requirements.

 

    	 	8	 

    	 

    

 

	11.	Notice

 

Any
notice shall be sent to the following addresses, with a copy also sent to the designated facsimile number. Notice shall be effective
on the date of receipt.

 

	 	Institution:
    	Thomas
    Jefferson University
	 	 	Office
    of Research Administration
	 	 	125
    South 9th Street
	 	 	Second
    Floor Sheridan 
	 	 	Philadelphia,PA
    19107 
	 	 	Attention:
    Director
	 	 	 
	 	 	FAX:
    215-503-2365
	 	 	 
	 	Principal
    Investigator: 	Saveri
    Bhattacharya, DO
	 	 	1015
    Chestnut Street, Suite 700
	 	 	Philadelphia,
    PA 19107
	 	 	 
	 	Sponsor:
    	BriaCell
    Therapeutics
	 	 	820
    Heinz Avenue
	 	 	Berkeley,
    CA 94710

 

	12.	Indemnification

 

 A. Sponsor agrees to indemnify, defend and hold harmless the Institution and its affiliates, Thomas Jefferson University Hospitals, Inc. and Jefferson University Physicians, IRB and each of their trustees, officers, staff, agents, employees, and Principal Investigator from any and all liabilities for: (a) personal injury (including death) or property damage arising out of or in connection with performance of the Study; (b) any type of claim or theory of product liability (including, without limitation, actions in tort, warranty or strict liability); (c) any patent infringement action relating, to Sponsor’s drugs, compounds or products used in the Study; or (d) Sponsor’s breach of its duties or obligations under this Agreement.

 

 B. The obligation of indemnification under this section shall not apply to the extent that liabilities are caused by (i) a failure of the Institution and/or Principal Investigator to use the Study Drug in accordance with the Protocol or other written instructions of Sponsor or (ii) the negligence or willful misconduct of the Principal Investigator or any other employee of Institution.

 

 C. Institution must promptly notify Sponsor of any claim or suit against any party to be indemnified hereunder, must allow Sponsor to have full control of any disposition or settlement of such claim or suit, and must fully cooperate with Sponsor regarding such disposition or settlement.

 

 D. Sponsor shall not dispose or settle any claim admitting liability on the part of the Institution without Institution’s prior consent.

 

    	 	9	 

    	 

    

 

	13.	Insurance

 

Sponsor
will maintain at all times a policy or policies of comprehensive general liability Insurance at levels sufficient to support the
indemnification obligations in this Agreement.

 

This
includes broad form and contractual liability and product liability, in a minimum amount of $1,000,000 per single occurrence and
$5,000,000 in the aggregate with respect to personal injury, bodily injury and property damage. Sponsor will provide Institution
with a certificate of insurance evidencing such coverage at the request of Institution.

 

	14.	Subject Injury (Not Applicable)

 

	15.	Termination

 

	A.	This
                                         Agreement may be terminated by either party for any reason upon thirty (30) days prior
                                         written notice, or in the manner and for the reason described in Article 2.

 

	B.	Termination
                                         of this Agreement by either party shall not affect the rights and obligations of the
                                         parties accrued prior to the effective date of the termination. The rights and duties
                                         under Articles 4, 5, 6, 7, 8, 9, 10, 11, 12, and 13 survive the termination or expiration
                                         of this Agreement.

 

	16.	Applicable Law

 

This
Agreement shall be governed by the laws of the Commonwealth of Pennsylvania, without regard to its principles of conflict of law.

 

	17.	No Agency

 

The
parties, in rendering performance under this Agreement, are each acting and shall act solely as independent contractors. Neither
party shall undertake by this Agreement or otherwise to perform any obligation of the other party, whether by regulation or contract.
In no way shall either party be construed as the agent or to be acting as the agent of the other party in any respect, any other
provisions of this Agreement notwithstanding. Neither party shall enter into any Agreement or incur any obligations on behalf
of the other party, nor commit the other party in any manner without such party’s prior written consent. Neither party shall
be deemed an employee of the other for the purposes of any employee benefit programs, income tax withholding, FICA taxes, unemployment
benefits, or otherwise.

 

	18.	No Assignment

 

Neither
party to this Agreement may, without the prior written consent of the non-assigning party, assign, transfer, subcontract, or sublicense
this Agreement or any obligation hereunder. Any attempt to do so in contravention of the Paragraph shall be void and of no force
and effect.

 

	19.	Force Majeure

 

Neither
party shall be liable for any failure to perform as required by this Agreement to the extent such failure to perform is due to
circumstances reasonably beyond such party’s control, including, without limitation, labor disturbances or labor disputes
of any kind, accident, failure of any governmental approval required for full performance, civil disorders or commotions, acts
of aggression, acts of God, energy or other conservation measures imposed by law or regulation, explosions, failure of utilities,
mechanical breakdowns, material shortages, disease, or other such occurrence.

 

    	 	10	 

    	 

    

 

	20.	Debarment

 

Institution
will not use in any capacity the services of any individual, corporation, partnership or association which:

 

		(1)	has
                                         been debarred under 21 U.S.C. 335a

 

		(2)	disqualified
                                         as a clinical investigator under the provision of 21 C.F.R. 312.70.

 

In
the event that Institution becomes aware of the debarment or disqualification of any such individual, corporation, partnership
or association providing services under this Agreement, Institution shall notify Sponsor.

 

	21.	Multiple Counterparts

 

This
Agreement may be executed in one or more counterparts, all of which shall be deemed an original and all of which when taken together
shall constitute one and the same instrument.

 

	22.	Section Headings: Exhibits

 

The
section and subsection headings used herein are for reference and convenience only, and shall not enter into the interpretation
hereof. The exhibits referred to herein and attached hereto, or to be attached hereto, are incorporated herein to the same extent
as if set forth in full herein.

 

	23.	Neutral Construction

 

The
parties to this Agreement agree that this Agreement was negotiated fairly between them at arm’s length and that the final
terms of this Agreement are the product of the parties’ negotiations. Each party warrants and represents that it has sought
and received legal counsel of its own choosing with regard to the contents of this Agreement and the rights and obligations affected
hereby. The parties agree that this Agreement shall be deemed to have been jointly and equally drafted by them, and that the provisions
of this Agreement therefore should not be construed against a party or parties on the grounds that the party or parties drafted
or was more responsible for drafting the provision(s).

 

	24.	No Waiver

 

No
delay or omission by either party hereto to exercise any right or power occurring upon any noncompliance or default by the other
party with respect to any of the terms of this Agreement shall impair any such right or power or be construed to be a waiver thereof.
The terms and conditions of this Agreement may be waived or amended only in writing and only by the party that is entitled to
the benefits of the term(s) or condition(s) being waived or amended. A waiver by either of the parties hereto of any of the covenants,
conditions, or Agreements to be performed by the other shall not be construed to be a waiver of any succeeding breach thereof
or of any covenant, condition, or Agreement herein contained (whether or not the provision is similar). Unless stated otherwise,
all remedies provided for in this Agreement shall be cumulative and in addition to and not in lieu of any other remedies available
to either party at law, in equity, or otherwise.

 

	25.	Unenforceability

 

If
any provision of this Agreement or any word, phrase, clause, sentence, or other portion thereof should be held to be unenforceable
or invalid for any reason, then provided that the essential consideration for entering into this Agreement on the part of any
party is not unreasonably impaired, such provision or portion thereof shall be modified or deleted in such manner as to render
this Agreement as modified legal and enforceable to the maximum extent permitted under applicable laws.

 

    	 	11	 

    	 

    

 

	26.	Entire Agreement

 

Each
party to this Agreement acknowledges that this Agreement constitutes the entire Agreement of the parties with regard to the subject
matters addressed in this Agreement, that this Agreement supersedes all prior or contemporaneous Agreements, discussions, or representations,
whether oral or written, with respect to the subject matter of this Agreement, and that this Agreement cannot be varied, amended,
changed, waived, or discharged except by a writing signed by all parties hereto. Each party to this Agreement further acknowledges
that no promises, representations, inducements, Agreements, or warranties, other than those set forth herein, have been made to
induce the execution of this Agreement by said party, and each party acknowledges that it has not executed this Agreement in reliance
on any promise, representation, inducement, or warranty not contained herein. The parties agree that in the event of a conflict
between the Protocol and this Agreement, the terms of this Agreement shall govern, except in the case of matters relating directly
to clinical procedures, with respect to which the terms of the Protocol shall prevail.

 

	27.	Authority To Enter Into Agreement

 

The
parties and their representatives signing this Agreement hereby acknowledge and represent that the representatives signing this
Agreement are duly authorized agents of the parties hereto and are authorized and have full authority to enter into this Agreement
on behalf of the parties for whom they are signing.

 

In
Witness Whereof, the parties hereto have executed this Agreement in duplicate by proper persons thereunto duly authorized.

 

	28.	Export Control

 

28.1
 Fundamental Research Limitation. The research developed and delivered by Collaborators
under Research Project performed under the Research Project in accordance with this Agreement, including all research data, inventions,
discoveries, copyrightable works, software, tangible materials and information, will be confined to “fundamental research”
as defined by International Traffic in Arms Regulations and Export Administration Regulations (collectively, “Export Control
Regulations”) and will therefore not be restricted under the Commerce Control List of the Export Control Regulations or
the US Munitions List of the International Traffic in Arms Regulations. Further, Institutions’ faculty and/or students who
are “foreign persons” shall not be restricted from participating in these research efforts pursuant to a Research
Project under this Agreement and should therefore not be subject to Export Control.

 

Should
Jefferson believe at some point that materials which are being developed under a Research Project subject to the terms of
this Agreement are deemed “export controlled”, Jefferson shall be required to provide specific information to the
appropriate authorities as to the regulation under which the materials are classified as controlled.

 

 28.2 Restricted Research. Should the Parties agree to conduct research that is not considered fundamental research as defined in US 15 Code of Federal Regulations Section 734.8 that is restricted in accordance with applicable export control laws, the Parties will negotiate terms under a joint working statement consistent with the handling and disclosure of data under terms more appropriate to restricted research.

 

    	 	12	 

    	 

    

 

 28.3 Exchange of Data. Either Party may make any use of any data of the other Party as it is required for purposes of fulfilling its responsibilities under the Agreement, subject to export control requirements and the US Government’s right to designate materials as classified. Where the Government wishes to make a non-public disclosure to an employee of the Parties designated as Proprietary Information, the US Government will first require the Institution to execute on behalf of the employee(s) a Non-Disclosure Agreement limiting the recipient’s use to be for purposes of fulfilling its responsibilities under this. Absent actual knowledge to the contrary, data that is not marked as being protected in accordance with the terms of this Agreement, shall be presumed to be unprotected and releasable to which the US Government will have unlimited rights.

 

 28.4 Software. To the extent not otherwise governed by US Patents and Copyrights laws and subject to export control requirements and US Government designated classified material guidelines, the developing Party will provide the other Party with the executable code, and minimum support documentation needed by a competent user to use software created in performance of a Research Project or for a joint working agreement under this Agreement for the sole purpose of performing the joint working agreement under this Agreement.

 

	THOMAS
    JEFFERSON UNIVERSITY	 	 BriaCell
    Therapeutics Corporation
	 	 	 	 	 
	By:	Ronald
F. Polizzi	 	By:
	William V. Williams
	 	      (signature)	 	 	      (signature)
	 	 	 	 	 
	 	Ronald
F. Polizzi	 	 	William
    V. Williams
	 	      (print
or type name)	 	 	      (print
    or type name) 
	 	 	 	 	 
	Title:	Director,
JCRI Business Operations	 	Title:
    	President and CEO
	Date:
    	March
12, 2020	 	Date:	2020 February 13

 

	Principal Investigator:	 
	(Read and Acknowledged)	 
	 	 	 
	By:
    	Saveri
    Bhattacharya, DO	 
	 	            (Signature)	 
	 	 	 
	By:	Saveri
    Bhattacharya, DO	 
	 	            (Print
    or Type Name)	 
	 	 	 
	Title:	Principal
    Investigator	 

 

    	 	13	 

    	 

    

 

EXHIBIT
A

 

Protocol
and Budget

 

 

THIS
PAGE SHOULD INCLUDE A COPY OF THE PROTOCOL AND THE BUDGET, INCLUDING PAYMENT SCHEDULE.

 

    	 	14Exhibit 42

		
			EXHIBIT 4.2
		

		
			﻿
		

		
			DESCRIPTION OF TILE SHOP HOLDINGS, INC. COMMON STOCK
		

		
			﻿
		

		
			The following summarizes the terms and provisions of the common stock of Tile Shop Holdings, Inc., a Delaware corporation (the “Company”), which common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  The following summary does not purport to be complete and is qualified in its entirety by reference to the Company’s Certificate of Incorporation and By-Laws, which the Company has previously filed with the Securities and Exchange Commission, and applicable Delaware law. 
		

		
			﻿
		

		
			Authorized Capital 
		

		
			﻿
		

		
			The Company’s authorized capital stock consists of 100,000,000 shares of common stock, $0.0001 par value per share (the “Common Stock”), and 10,000,000 shares of preferred stock, $0.0001 par value per share (the “Preferred Stock”).  
		

		
			﻿
		

		
			Under Delaware law, stockholders generally are not personally liable for a corporation’s acts or debts. 
		

		
			﻿
		

		
			Common Stock
		

		
			﻿
		

		
			Dividend Rights
		

		
			﻿
		

		
			Subject to preferences that may be applicable to any then-outstanding shares of Preferred Stock, the holders of Common Stock are entitled to receive such dividends, if any, as may be declared from time to time by the Company’s Board of Directors out of legally available funds.
		

		
			﻿
		

		
			Voting Rights 
		

		
			﻿
		

		
			Holders of Common Stock are entitled to one vote for each share held of record on all matters to be voted on by the stockholders, including the election of directors. There is no cumulative voting with respect to the election of directors. Directors are elected by a plurality of the votes cast by the holders of Common Stock. Except as otherwise required by law or the Company’s Certificate of Incorporation or By-Laws, all other matters brought to a vote of the holders of Common Stock are determined by a majority of the votes cast and, except as may be provided with respect to any other outstanding class or series of the Company’s stock, the holders of shares of Common Stock possess the exclusive voting power.
		

		
			﻿
		

		
			Liquidation 
		

		
			﻿
		

		
			In the event of the Company’s liquidation, dissolution or winding up, the holders of Common Stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of the Company’s known debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of Preferred Stock.
		

		
			﻿
		

		
			Rights and Preferences
		

		
			﻿
		

		
			All outstanding shares of Common Stock are duly authorized, fully paid and non-assessable. Holders of Common Stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to the Common Stock. The rights, preferences, and privileges of the holders of Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of Preferred Stock that the Company may designate in the future.
		

		
			﻿
		

		
			Quotation
		

		
			﻿
		

		
			The Common Stock is quoted on the Pink tier of the OTC Markets under the symbol “TTSH.”
		

		
			﻿
		

		
			﻿
		

		

		

		 

 

		Preferred Stock
		

		
			﻿
		

		
			The Board of Directors has the authority, without further action by the holders of Common Stock, to issue up to 10,000,000 shares of Preferred Stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of Common Stock. The issuance of Preferred Stock could adversely affect the voting power of holders of Common Stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of Preferred Stock could have the effect of delaying, deferring, or preventing a change of control of the Company or other corporate action. The Company has no outstanding shares of Preferred Stock. 
		

		
			﻿
		

		
			Anti-Takeover Effects of Provisions of Delaware Law and the Company’s Certificate of Incorporation and By-Laws
		

		
			﻿
		

		
			Certificate of Incorporation and By-Laws
		

		
			﻿
		

		
			The Company’s Certificate of Incorporation provides for the Company’s Board of Directors to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because the Company’s stockholders do not have cumulative voting rights, its stockholders holding a majority of the shares of Common Stock outstanding will be able to elect all of its directors. The Company’s Certificate of Incorporation and By-Laws provide that all stockholder actions must be effected at a duly called meeting of stockholders and not by a consent in writing, and that only the Company’s Board of Directors, Chairperson of the Board of Directors, Chief Executive Officer or President may call a special meeting of stockholders.
		

		
			﻿
		

		
			The Company’s Certificate of Incorporation provides that certain provisions of the Company’s Certificate of Incorporation, including those relating to the issuance of Preferred Stock, classification of the Board of Directors, and the inability of the stockholders to take action by written consent or call a special meeting, may only be altered, amended, repealed or replaced only with the affirmative vote of the holders of at least 75% of the voting power of all of the then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors. The Company’s Certificate of Incorporation and By-Laws further provide that the Company’s By-Laws may be altered, amended, repealed or replaced by the Board of Directors without stockholder approval, to the extent permitted by law; provided, however, that the stockholders may amend the By-Laws with the affirmative vote of the holders of at least 75% of the voting power of all of the then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors. The Company’s Certificate of Incorporation and By-Laws also provide that stockholders may only remove a director for cause and only by the affirmative vote of the holders of at least 75% of the voting power of all of the then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors. The Company’s Certificate of Incorporation and By-Laws allow the Company’s directors to establish the size of the Board of Directors and fill vacancies on the Board, including those created by an increase in the number of directors (subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances). The Company’s By-Laws establish advance notice procedures for stockholders to submit proposals and nominations of candidates for election to the Board of Directors to be brought before a stockholders’ meeting. The combination of the classification of the Board of Directors, the lack of cumulative voting or the ability of stockholders to take action by written consent or call a special meeting, the 75% stockholder voting requirements, the limitations on removing directors without cause, the ability of the Board of Directors to fill vacancies, and the advance notice provisions make it difficult for the Company’s existing stockholders to replace its Board of Directors, as well as for another party to obtain control of the Company by replacing its Board of Directors. Because the Company’s Board of Directors has the power to retain and discharge its officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated Preferred Stock makes it possible for the Company’s Board of Directors to issue Preferred Stock with voting or other rights or preferences that could impede the success of any attempt to change the Company’s control.
		

		
			﻿
		

		
			These provisions may have the effect of deterring hostile takeovers or delaying changes in the Company’s control or management. 
		

		

		

		 

 

		﻿
		

		
			Delaware Anti-Takeover Law
		

		
			The Company is not currently subject to Section 203 of the Delaware General Corporation Law (“Section 203”), which generally prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder unless:
		

		
			﻿
		

			
	
			
				 ·
			

			
	
			
			prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;

		
			﻿
		

			
	
			
				 ·
			

			
	
			
			upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned by (i) persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

		
			﻿
		

			
	
			
				 ·
			

			
	
			
			on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder.

		
			﻿
		

		
			In general, Section 203 defines “business combination” to include the following:
		

		
			﻿
		

			
	
			
				 ·
			

			
	
			
			any merger or consolidation involving the corporation and the interested stockholder;

		
			﻿
		

			
	
			
				 ·
			

			
	
			
			any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions), except proportionately as a stockholder of such corporation, to or with the interested stockholder, of assets of the corporation, which assets have an aggregate market value equal to 10% or more of either the aggregate market value of all the assets of the corporation determined on a consolidated basis or the aggregate market value of all the outstanding stock of the corporation;

		
			﻿
		

			
	
			
				 ·
			

			
	
			
			subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

		
			﻿
		

			
	
			
				 ·
			

			
	
			
			subject to certain exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the interested stockholder’s proportionate share of the stock of any class or series, or securities convertible into the stock of any class or series, of the corporation; and

		
			﻿
		

			
	
			
				 ·
			

			
	
			
			any receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

		
			﻿
		

		
			In general, Section 203 defines an “interested stockholder” as an entity or person that, together with the person’s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.
		

		
			﻿
		

		
			Authorized and Unissued Shares
		

		
			﻿
		

		
			The Company’s authorized and unissued shares of Common Stock are available for future issuance without stockholder approval except as may otherwise be required by applicable regulations or Delaware law.  The Company may issue additional shares for a variety of purposes, including future offerings to raise additional capital, to fund acquisitions and as employee and consultant compensation. The existence of authorized but unissued shares 
		

		 

 

		of Common Stock could render more difficult, or discourage an attempt, to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise.
		

		
			﻿
		

		
			The issuance of shares of Preferred Stock by the Company could have certain anti-takeover effects under certain circumstances, and could enable the Board of Directors to render more difficult or discourage an attempt to obtain control of the Company by means of a merger, tender offer or other business combination transaction directed at the Company by, among other things, placing shares of Preferred Stock with investors who might align themselves with the Board of Directors.
		

		
			﻿

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]